Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort

Summary

Severe postpartum haemorrhages (PPH) are responsible for maternal morbidity/mortality. Their complex management sometimes requires haemostatic supplementation, and therapeutic trials on fibrinogen or activated factor VII, which may add to the thrombotic risk, are currently being considered. Furthermore, there is a risk of venous thromboembolism (VTE) during the postpartum period, hence we studied the relationship between severe PPH and VTE in women during their first pregnancy. Among the 32,463 women enrolled between January 1, 1999 and February 1, 2004 in the NOHA First cohort, 317 developed severe PPH, 11 postpartum VTE and 60 had postpartum superficial vein thrombosis (SVT). In the women with severe PPH, whilst there were no episodes of VTE, there were three episodes of SVT, which occurred 6 weeks postpartum. All of the women with severe PPH received packed red blood cell (RBC) units, 29 (9.1%) platelets units, 51 (16.1%) fresh frozen plasma and 29 (9.1%) fibrinogen concentrates. Three patients with both severe PPH and SVT received only packed RBC. Severe PPH or packed RBC unit transfusion were associated with postpartum SVT (adjusted relative risk: 5.3 (1.6–17) and 4.7 (1.5–15) respectively), independent of caesarean section delivery and low-molecular- weight heparin (LMWH) use in the postpartum, but were not independent indicators of one another. This the VTE and SVT risks associated with severe PPH are low (<1% and <2%, respectively).Severe PPH increases the risk of postpartum SVT, but transfusion with platelet units and plasma supplementation using fresh frozen plasma or fibrinogen concentrates do not markedly modulate the risk of venous thrombosis.

Keywords

Postpartum haemorrhage - thrombosis - deep vein thrombosis - superficial vein thrombosis

• References

• 1 Zhang WH, Alexander S, Bouvier-Colle MH. et al. and the MOMS-B Group. Incidence of severe preeclampsia, postpartum haemorrhage as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey. BJOG 2005; 102: 89-96.
• 2 Hazra S, Chilaka VN, Rajendran S. et al. Massive postpartum haemorrhage as a cause of maternal morbidity in a large tertiary hospital. J Obstet Gynaecol 2004; 24: 519-520.
• 3 Deneux-Tharaux C, Dreyfus M, Goffinet F. et al. and le groupe Euphrates. Prevention and early management of iommediate postpartum haemorrhage: Policies in six perinatal networks in France. J Gynecol Obstet Biol Reprod (Paris) 2008; 37: 237-245.
• 4 Winter C, Macfarlane A, Deneux-Tharaux C. et al. Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe. BJOG 2007; 114: 845-854.
• 5 Charbit B, Mandelbrot L, Samain E. et al. for the PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum haemorrhage. J Thromb Haemost 2006; 05: 266-273.
• 6 Vincent JL, Rossaint R, Riou B. et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding -a European perspective. Crit Care 2006; 10: R120.
• 7 Pomp ER, Lenselink AM, Rosendaal FR. et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 06: 632-637.
• 8 Heit JA, Kobbervig CE, James AH. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
• 9 Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvelon E. et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control “NOHA First” study. J Thromb Haemost 2005; 03: 2178-2184.
• 10 Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G. et al. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for thrombosis during the first pregnancy. J Thromb Haemost 2007; 04: 700-707.
• 11 Langer B, Bourdier E, Haberstish R. et al. Obstetrical management in the event of persistent or worsening postpartum haemorrhage despite initial measures [French]. J Gynecol Obstet Biol Reprod 2004; 33: 4S73-4S79.
• 12 Jacobsen AF, Skjeldestad FE, Sandset PM. Anteand postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 06: 905-919.
• 13 James AH, Jamison MG, Brancazio LR. et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315.
• 14 Geerts WH, Code KI, Jay RM. et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331: 1601-1606.
• 15 Rogers Jr. SO, Kilaru RK, Hosokawa P. et al. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204: 1211-1221.
• 16 Kreuz W, Meili E, Peter-Salonen K. et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transf Apher Sci 2005; 32: 247-253.
• 17 Haberer JP, Obstler C, Samama CM. et al. Postoperative deep vein thrombosis in a woman with constitutional afibrinogenemia treated with fibrinogen concentrates. Eur J Anaesthesiol 2008; 25: 519-521.
• 18 Lak K, Keihani M, Elahi F. et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenemia. Br J Haematol 1999; 107: 204-206.
• 19 Girolami A, Ruzon E, tezza F, Scandellari R. et al. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006; 12: 345-351.
• 20 Simsek I, de Mazancourt P, Horellou MH. et al. Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes. Blood Coagul Fibrinolysis 2008; 19: 247-253.
• 21 Dupuy E, Soria C, Molho P. et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-219.